{
    "clinical_study": {
        "@rank": "77391", 
        "arm_group": [
            {
                "arm_group_label": "XM02 filgrastim and high dose melphalan", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose melphalan", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase II randomized study to test the safety and efficacy of the recombinant G-CSF XM-02\n      filgrastim (Granix) plus high dose melphalan versus high dose melphalan alone prior to\n      autologous stem cell transplant."
        }, 
        "brief_title": "XM02 Filgrastim to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation", 
        "completion_date": {
            "#text": "October 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic multiple myeloma requiring treatment\n\n          -  Received at least two cycles of any regimen as initial systemic therapy for multiple\n             myeloma and are within 2-12 months of the first dose of initial therapy\n\n          -  At least 18 years of age\n\n          -  Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved,\n             peripheral blood stem cell collection containing at least 2 \u00d7 106 CD34+ cells/kg\n             based on patient body weight.\n\n          -  Adequate organ function as measured by:\n\n          -  Cardiac function: Left ventricular ejection fraction at rest \u226540%\n\n          -  Hepatic function: Bilirubin \u22642 \u00d7 ULN and aspartate amino transferase/alanine amino\n             transferase (AST/ALT) \u22643 \u00d7 ULN\n\n          -  Renal function: Creatinine clearance \u226540 mL/minute (measured or calculated/estimated)\n\n          -  Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for\n             hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory\n             vital capacity (FVC) \u226550% of predicted value\n\n          -  Oxygen saturation \u226592% on room air\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.\n\n          -  Able to understand and willing to sign an IRB-approved written informed consent\n             document\n\n        Exclusion Criteria:\n\n          -  Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior\n             to ASCT\n\n          -  Prior stem cell transplant (autologous or allogeneic)\n\n          -  Smoldering MM not requiring therapy\n\n          -  Plasma cell leukemia\n\n          -  Systemic amyloid light chain amyloidosis\n\n          -  Active bacterial, viral, or fungal infection\n\n          -  Seropositive for human immunodeficiency virus (HIV)\n\n          -  Known, active hepatitis A, B, or C Infection\n\n          -  Pregnant or breastfeeding.\n\n          -  Receiving other concurrent anticancer therapy (including chemotherapy, radiation,\n             hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days\n             prior to the ASCT or planning to receive any of these treatments prior to the last\n             study visit on Day +100.\n\n          -  Hypersensitive or intolerant to any component of the study drug(s) formulation\n\n          -  Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor,\n             etc) or undergoing apheresis < 14 days prior to the start of treatment on protocol\n             (Day -7).\n\n        Inclusion of Women and Minorities\n\n        -Both men and women and members of all races and ethnic groups are eligible for this\n        trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "176", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112045", 
            "org_study_id": "14-X003"
        }, 
        "intervention": [
            {
                "arm_group_label": "XM02 filgrastim and high dose melphalan", 
                "description": "XM02 filgrastim 5 mcg/kg on Days -7 through -2 Melphalan 100 mg/m2 on Days -3 through -2", 
                "intervention_name": "XM02 filgrastim and high dose melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Granix", 
                    "Alkeran\u00ae Tablets", 
                    "Phenylalanine mustard"
                ]
            }, 
            {
                "arm_group_label": "High dose melphalan", 
                "description": "Melphalan 100 mg/m2 on Days -3 through -2", 
                "intervention_name": "High dose melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran\u00ae Tablets", 
                    "Phenylalanine mustard"
                ]
            }, 
            {
                "arm_group_label": [
                    "XM02 filgrastim and high dose melphalan", 
                    "High dose melphalan"
                ], 
                "description": "Stem Cell infusion Day 0", 
                "intervention_name": "Autologous Stem Cell Transplant", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Melphalan", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "rvij@dom.wustl.edu", 
                "last_name": "Ravi Vij, M.D.", 
                "phone": "314-454-8304"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Camille Abboud, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amanda Cashen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Christopher, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John DiPersio, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd Fehniger, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Meagan Jacoby, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Iskra Pusic, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rizwan Romee, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mark Schroeder, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keith Stockerl-Goldstein, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Micheal Tomasson, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Geoffrey Uy, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Walter, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lucas Wartman, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Welch, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Peter Westervelt, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of XM02 Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation", 
        "overall_contact": {
            "email": "rvij@dom.wustl.edu", 
            "last_name": "Ravi Vij, M.D.", 
            "phone": "314-454-8304"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Ravi Vij, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete response (CR) requires all of the following:\nDisappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine\n<5% plasma cells in the bone marrow\nDisappearance of soft tissue plasmacytomas\nStringent complete response (sCR) requires all of the following:\nCR as defined above\nNormal free light chain ratio\nAbsence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence", 
            "measure": "CR and sCR", 
            "safety_issue": "No", 
            "time_frame": "100 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "measure": "Toxicity of XM-02 filgrastim + (High Dose Melphalan) HDM to HDM alone", 
                "safety_issue": "Yes", 
                "time_frame": "107 days"
            }, 
            {
                "description": "Complete response (CR), disappearance of monoclonal protein from the blood & urine and <5% plasma cells in bone marrow &disappearance of soft tissue plasmacytomas\nStringent complete response (sCR), CR & normal free light chain ratio & absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence\nVery good partial response (VGPR), serum and urine monoclonal protein detectable by immunofixation but not on electrophoresis OR > 90% reduction in serum monoclonal protein with urine monoclonal protein < 100 mg per 24 hours and if present, > 50% reduction in the size of soft tissue plasmacytomas\nPartial response (PR), > 50% reduction in the level of the serum monoclonal protein & reduction in urine monoclonal protein & > 50% reduction in the size of soft tissue plasmacytomas & if serum and urine monoclonal protein are unmeasurable and serum free light chain is unmeasurable, a > 50% reduction in plasma cells is required", 
                "measure": "Overall Response Rate (CR+ sCR) + VGPR + PR", 
                "safety_issue": "No", 
                "time_frame": "2 years 3 months"
            }, 
            {
                "description": "Overall survival (OS) is defined as the duration from the time of transplant Day 0 to death or last follow-up.", 
                "measure": "Overall survival comparing XOM filgratim + HDM  to HDM alone", 
                "safety_issue": "No", 
                "time_frame": "2 years 3 months"
            }, 
            {
                "description": "Progression-free survival (PFS) is defined as the duration from time of transplant Day 0 to time of first progression/clinical relapse, death, or the date the patient was last known to be in remission", 
                "measure": "Progression=free survival comparing XOM filgratim + HDM  to HDM alone", 
                "safety_issue": "No", 
                "time_frame": "2 years 3 months"
            }, 
            {
                "description": "Neutrophil engraftment is defined as ANC \u2265 0.5 \u00d7 109/L \u00d7 3 consecutive daily assessments. The first of 3 consecutive days for which ANC \u2265 0.5 \u00d7 109/L will be recorded as the date of neutrophil engraftment. Time to neutrophil engraftment will be calculated as the time from the date of the ASCT to the date of neutrophil engraftment.", 
                "measure": "Neutrophil engraftment  comparing XOM filgratim + HDM  to HDM alone", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Platelet engraftment is defined as an untransfused platelet measurement >20,000/mm3 \u00d7 3 consecutive daily assessments. The first of 3 consecutive days for which the untransfused platelet measurement is >20,000/mm3 will be recorded as the date of platelet engraftment. Time to platelet engraftment will be calculated as the time from receiving the date of ASCT to the date of platelet engraftment.  Untransfused is defined as no transfusions within 7 days.", 
                "measure": "Platelet engraftment comparing XOM filgratim + HDM  to HDM alone", 
                "safety_issue": "Yes", 
                "time_frame": "100 days"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}